Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis
Celine van de Laar, researcher at TiH, presented a poster comparing the long-term cost-effectiveness of different treat-to-target therapies in rheumatoid arthritis at the 2017 ACR/ARHP Annual Meeting in San Diego, California. The study that used data from the DREAM registry, showed that over a period of 5 years initial combination therapy resulted in lower costs and better quality of life compared to step-up therapy.
The poster abstract can be downloaded here.
Watch a video from iDoctor where Celine explains the poster here (in Dutch).